Tafamidis ATTR denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Tafamidis (ATTR) as Experimental

Aetna's experimental or investigational denial for tafamidis means Aetna's reviewers determined — under the criteria in their clinical policy bulletin — that the evidence does not meet their threshold for established benefit in your specific clinical situation. For tafamidis used in transthyretin amyloid cardiomyopathy (ATTR-CM), this denial is uncommon given the drug's FDA approval and the strength of evidence recognized by major cardiology societies. It is more likely to appear when the indication in your chart is less precisely documented, or when Aetna's clinical policy has not been updated in response to new guideline endorsements.

Tafamidis holds FDA approval for ATTR-CM. An experimental denial for an FDA-approved drug used within its approved indication is a strong candidate for appeal, particularly given the endorsement of its use by leading cardiovascular professional organizations.

## Your Federal Appeal Rights

• Internal appeal: File within the window on your denial notice. Request — in writing — the specific Aetna clinical policy bulletin number, version date, and the exact criterion used to classify tafamidis as experimental in your case.
• External review (ACA §2719): Non-grandfathered plans must offer independent external review following a final internal denial. The external reviewer, an independent clinician, will assess whether the experimental classification is clinically supportable. The filing window is generally approximately four months from the final internal denial.
• ERISA §503: Employer-plan members have the right to a full-and-fair review, including access to all plan documents and clinical guidelines used.
• Expedited review: ATTR-CM is a progressive, life-threatening cardiac condition. If delay creates a serious health risk, request expedited review at every level simultaneously.

## What to Gather

1. FDA approval documentation: Obtain the current FDA prescribing information for tafamidis from DailyMed (dailymed.nlm.nih.gov). Confirm the approved indication matches your documented diagnosis and include this as an exhibit. 2. Diagnosis and staging records: Cardiology records confirming your ATTR-CM or ATTR-PN diagnosis, including imaging, biopsy results (if available), and functional classification. 3. Guideline organization support: Your cardiologist should reference the applicable ACC/AHA guideline organization's current recommendation for tafamidis in ATTR-CM in the prescriber letter. Do not cite specific numbers or version dates without verifying them in the current published guideline. 4. Prescriber medical-necessity letter: Your treating cardiologist should attest that the use is within the FDA-approved indication, that leading cardiovascular guideline organizations endorse this therapy for your disease stage, and should directly rebut Aetna's experimental classification criterion by criterion.

## Criteria-Mapping Structure

Request and then download Aetna's clinical policy bulletin for tafamidis. Map each experimental classification criterion to a rebuttal:

| Aetna Experimental Criterion | Rebuttal Evidence | |---|---| | [Specific criterion from CPB] | [FDA label / guideline org reference / chart documentation] |

Submitting this structured rebuttal alongside the prescriber letter and FDA label gives an external reviewer everything needed to overturn the denial — and makes the internal reviewer's job of upholding it much harder.